RegeneRx Updates Schedule for Release of Clinical Trial Information
News Dec 26, 2008
Regenerx Biopharmaceuticals, Inc. has announced an updated schedule for the release of information related to certain of its ongoing clinical trials.
RegeneRx currently estimates that it will report on its Phase II pressure ulcer trial evaluating RGN-137 by mid-January 2009; on its Phase II venous stasis ulcer trial, also evaluating RGN-137, in February 2009; and on its Phase I parenteral trial evaluating RGN-352 in March 2009.
RGN-137 is a topical gel formulation of Tß4 being developed for dermal wound healing and RGN-352 is an injectable formulation of Tß4 being developed for internal indications such as acute myocardial infarction.
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE